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There is currently a lack of reliable diagnostic and prognostic markers for ovarian cancer. We established gene expression profiles for
120 human ovarian tumours to identify determinants of histologic subtype, grade and degree of malignancy. Unsupervised cluster
analysis of the most variable set of expression data resulted in three major tumour groups. One consisted predominantly of benign
tumours, one contained mostly malignant tumours, and one was comprised of a mixture of borderline and malignant tumours. Using
two supervised approaches, we identified a set of genes that distinguished the benign, borderline and malignant phenotypes. These
algorithms were unable to establish profiles for histologic subtype or grade. To validate these findings, the expression of 21 candidate
genes selected from these analyses was measured by quantitative RT–PCR using an independent set of tumour samples. Hierarchical
clustering of these data resulted in two major groups, one benign and one malignant, with the borderline tumours interspersed
between the two groups. These results indicate that borderline ovarian tumours may be classified as either benign or malignant, and
that this classifier could be useful for predicting the clinical course of borderline tumours. Immunohistochemical analysis also
demonstrated increased expression of CD24 antigen in malignant versus benign tumour tissue. The data that we have generated will
contribute to a growing body of expression data that more accurately define the biologic and clinical characteristics of ovarian
cancers.
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Ovarian cancer is newly diagnosed in approximately 25000 women
annually in the US and is associated with nearly 15000 deaths. These
grim statistics underscore the need for advances in the development
of diagnostic and prognostic markers in addition to new therapeutic
approaches. Common epithelial ovarian tumours, which account for
the majority of all ovarian neoplasms, are classified as benign,
borderline or malignant according to their histology and clinical
behaviour (Ozols et al, 1997). They are also subdivided into at least
seven histological subtypes. Serous tumours account for nearly half
of all epithelial ovarian tumours, followed by mucinous, endome-
trioid and clear cell subtypes, respectively. Of the four major
histologic subtypes, serous tumours are associated with the lowest
five-year survival rate (20–35%) compared to mucinous (40–60%),
endometrioid (40–60%) and clear cell tumours (35–50%). Each
subtype may be graded to reflect the extent of architectural and
cytoplasmic features of differentiation. The histologic grade is of
more prognostic significance than subtype, because a higher five-
year survival is associated with well-differentiated tumours (70–
80%) in comparison to moderate (30–45%) or poorly differentiated
tumours (20%). Although, the histologic subtype, grade and degree
of malignancy have significant implications for ovarian cancer
patients, there are a number of other important prognostic factors
including disease stage, volume of residual disease following
debulking surgery, age, performance status and the type of
chemotherapy used in treatment (Friedlander, 1998).
Borderline tumours, or tumours of low malignant potential
(LMP), have a histologic appearance that lies between that of the
benign and malignant phenotypes. These tumours, which account
for 10–20% of common epithelial tumours, are characterised by a
high proliferation rate without stromal invasion (Trope and Kaern,
1998). The prognosis for women with borderline tumours is
excellent; however, a significant percentage (10–15%) of border-
line tumours will become malignant and result in fatality. As these
tumours are relatively rare and afflict younger women, the issue of
sparing fertility is important and affects the clinical management
of this disease. Although borderline tumours are officially accepted
as a tumour type, considerable debate persists over how to
diagnose them accurately and predict their clinical course.
Therefore, the identification of reliable molecular markers is
necessary to select the cohort of borderline patients that are more
likely to develop malignant disease. Women with a higher risk of
recurrence could then be treated more aggressively to reduce the
mortality rate observed for this group.
Overall, there is a lack of specific markers for classifying the
clinical and biologic characteristics of ovarian tumours. Although
CA125 has been a useful marker for documenting disease response
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sand progression, it has limited use as a diagnostic tool (Meyer and
Rustin, 2000). The advent of expression profiling and proteomic
technologies has the benefit of enabling investigators to identify
groups of genes and proteins that may be used as classifiers. To
date, only a few large studies have used these techniques in an
attempt to classify ovarian tumours with respect to subtype, grade
and degree of malignancy (Welsh et al, 2001; Schwartz et al, 2002;
Schaner et al, 2003; Adib et al, 2004). In the present study, we have
examined the expression of approximately 7000 genes in a panel of
120 human ovarian tumours that represent various histologic
subtypes, grades and degrees of malignancy. An analysis of the
data has revealed specific classifiers for some of these phenotypes.
These profiles ultimately contribute to a growing consensus of
diagnostic and prognostic markers for ovarian cancer and may
provide targets for therapeutic intervention.
MATERIALS AND METHODS
Tumour specimens
Over 200 frozen human ovarian tumour specimens were obtained
from the Cooperative Human Tissue Network. The specimens were
obtained from patients through an informed consent protocol and
patient identity remained anonymous. We requested tumours
representing a representative range of histologic type, grade and
degree of malignancy. The pathology information used in this
study was obtained from the accompanying pathology report.
Total RNA was isolated with Trizol reagent (Invitrogen, Carlsbad,
CA, USA) according to the procedure provided by the manufac-
turer. Each sample was evaluated for integrity by agarose gel
electrophoresis; only the samples with intact 18S and 28S
ribosomal RNA bands were used. RNA (2–5mg) was linearly
amplified using a modified amplification procedure originally
described by Van Gelder et al (1990). Only samples that yielded
sufficient quantities of amplified RNA (approximately 5mg) were
used for expression profiling.
Microarray analysis
Fluorescent cDNA probes were prepared based on the Cy3/Cy5
indirect labelling procedures described previously (Schena et al,
1995; Hegde et al, 2000). As a reference for each sample, we
prepared a pooled common reference containing ovarian tumour
RNA mixed with Universal Reference RNA (Stratagene Inc., La
Jolla, CA, USA). Amplified RNA (5mg) was combined in a 1.5ml
microcentrifuge tube with 5mg oligo-dT (Invitrogen) in a final
volume of 17.4ml, incubated at 651C for 10min, and placed on ice
for 5min. The cDNA synthesis reaction consisted of a mixture of
6.0ml5 First Strand buffer (Invitrogen), 3.0ml 0.1 M DTT, 0.6ml
aminoallyl-dUTP/dNTP mix, 1ml RNasin and 2.0ml Superscript II
reverse transcriptase (200U/ml). Samples were incubated at 421C
for 2.0h. RNA was degraded by adding 10mlo f1 N NaOH and
incubating the samples at 651C for 15min. Following neutralisa-
tion with 10ml1 N HCl, the cDNA was precipitated in ethanol,
vacuum-dried, and resuspended in 9ml 0.1 M sodium bicarbonate
(pH 9.0). The samples were incubated with Cy5 or Cy3 dye
(Amersham, Piscataway, NJ, USA) for 1h in the dark at room
temperature, and the reactions were quenched with the addition of
4.5mlo f4 M hydroxylamine. Finally, the reaction products were
purified using a QIA-quick PCR purification kit, vacuum-dried,
and resuspended in 35ml hybridisation buffer (40% formamide,
5 SSC, 0.1% N-laurylsarcosine).
Approximately 7000 DNA fragments were successfully amplified
by PCR using the GF211/GF212 clone sets obtained from
Invitrogen (formerly Research Genetics). After purification of the
DNA, printing plates were prepared by mixing DNA in an equal
volume with DMSO. Glass slide (UltraGap Slides, Corning Inc.,
Corning, NY, USA) arrays were prepared by printing DNA
fragments in duplicate using an Omnigrid Accent arrayer
(Genomic Solutions, Ann Harbor, MI, USA). Post-processing
of the slides included UV irradiation followed by 1h incubation at
801C in a vacuum oven. Prior to use, slides were prehybridised for
2h at 371Ci n5  SSC containing 1% (w/v) SDS and 1% (w/v)
bovine serum albumin. For hybridisation, samples were incubated
at 1001C for 5min and placed at 421C for 20min. Following
brief centrifugation, the samples were applied to the microarray
slide, which was overlaid with a coverslip and incubated overnight
at 421C in a hybridisation chamber. The slides were washed
once with 5 SSC, 0.1% N-laurylsarcosine at 371C for 5min,
followed by three 5min washes with 0.1 SSC at room
temperature. The slides were centrifuged to dryness and scanned
using an Axon GenePix 4000B scanner (Axon Instruments, Union
City, CA, USA).
The raw data were uploaded into Microsoft Excel for analysis.
The data were cleaned to eliminate flagged spots. The sample and
reference channels were then balanced based on the total
fluorescence intensity of the remaining values. As the microarray
slides were spotted in duplicate, an average intensity value was
calculated for each cDNA element. If the average error between the
two spots was 20%, the value was eliminated. Only values were
retained in which duplicate intensity measurements were available.
The data were normalised by global means normalisation; there-
fore, the mean of all the averaged values on the array was equal to
one. The data were cropped to contain only the cDNA elements
that yielded values in at least 80% of the tumour specimens. This
final data set was analysed by several statistical algorithms
including the Cluster and Tree View programs developed by Eisen
et al (1998), Prediction Analysis of Microarrays (PAM) program
developed by Tibshirani et al (2002), and by Student’s t-test.
Quantitative RT–PCR
Relative gene expression was measured in each of the cell lines by
‘real time’ quantitative PCR by the use of a LightCycler (Roche
Diagnostics Corp., Indianapolis, IN, USA) with SYBR green
chemistry. Reaction conditions were optimised for each primer
set. Measurements were made in duplicate and normalised
based on the average expression of six housekeeping genes
(ubiquitin-specific protease 21, ornithine decarboxylase, chaper-
onin-containing TCP1 subunit 3, glutamate dehydrogenase 1,
lactate dehydrogenase A and eukaryotic translation initiation
factor 2). Primer sequences and reaction conditions are listed at
www.realtimeprimers.org.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissues were obtained from the
Cooperative Human Tissue Network (University of Pennsylvania,
Philadelphia, PA, USA), dewaxed with xylene, and gradually
hydrated. Antigen retrieval was achieved by pressure-cooking in
citrate buffer (0.01 M, pH 6) for 10min. The slides were washed and
pretreated with Dako Cytomation endogenous peroxidase blocking
solution (Hamburg, Germany) for 10min. Dako Cytomation non-
specific antigen blocking protein substrate (Hamburg, Germany)
was subsequently applied, and the slides were incubated at room
temperature for 15min. Slides were subsequently incubated with
either a 1:50 dilution of mouse-anti-CD24 antibody (Santa Cruz –
SC7034) or a 1:200 dilution of rat-anti-SPARCL1 antibody (SC1,
MAST9, Hevin, clone 12–51 supplied by Dr Helene Sage) (Brekken
et al, 2004) for 1h at room temperature. After washing and
incubation with the appropriate HRP-coupled secondary antibody,
detection was carried out using a BD Pharmingen DAB Substarate
kit (San Diego, CA, USA) according to the manufacturer’s
instructions. Slides were counter-stained with haematoxylin.
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Specimens and data analysis
We established expression profiles for 120 human ovarian tumours
obtained from the Cooperative Human Tissue Network. The
pathologic characteristics of these tumours are shown in Table 1.
The majority of the specimens represented malignant tumours
(48%); however, a large percentage of benign (24%) and borderline
(28%) tumours was also analysed. With respect to tumour subtype,
the cohort consisted primarily of mucinous tumours (42%),
followed by serous (23%), clear cell (17%) and endometrioid
(9%) subtypes, whereas seven (6%) of the tumours contained a
mixture of at least two subtypes. The accompanying pathology
reports contained information regarding histologic grade (Table 1).
Total RNA was isolated from whole tumour specimens and the
integrity of each sample was assessed by agarose gel electrophor-
esis. We observed that approximately 60% of the tumour
specimens yielded intact RNA and only these were subjected to
cDNA microarray analysis. Each array contained approximately
7000 genes spotted in duplicate. The resulting data set was cleaned
and processed to include only the expression values that (a)
differed by 20% between duplicates, and (b) for which data were
obtained from at least 80% of the specimens. The data was then
batch-corrected and median-normalised. These processing steps
resulted in a final data set containing expression values for 5494
cDNA elements.
Unsupervised classification
Hierarchical clustering was applied to the most variable portion of
the data to determine whether the phenotypic features of ovarian
tumours could be readily distinguished (Figure 1). Three major
groups resulted from this analysis and the relative percentages of
the benign, borderline and malignant tumours present in each
group are shown. Group I contained predominantly benign and
borderline tumours (56 and 26%, respectively), while few
malignant tumours were present. Group II contained a high
percentage of malignant tumours (83%), but few benign or
borderline tumours were present. Group III was heterogeneous
and contained similar percentages of borderline (40%) and
malignant tumours (50%) and relatively few benign tumours
(10%). The genes that were increased in expression and associated
with groups I and II relative to the other tumour samples are listed
in Table 2. This unsupervised clustering algorithm did not clearly
distinguish the tumours based on subtype or histologic grade.
However, group II contained mostly serous and endometrioid
tumours, whereas group III contained a higher percentage of clear
cell and mucinous tumours. The average grade of the tumours in
group II was moderate to poor, whereas the average grade of the
tumours in group III was moderate. The entire data set and
detailed dendograms for Figure 1 are available in the (Supple-
mentary Figures S1 and S2).
Supervised classification
The PAM program was used to develop a classifier for the benign,
borderline and malignant phenotypes (Tibshirani et al, 2002). This
algorithm represents a modification of the nearest-centroid
method and identifies genes that best characterise each class.
From this analysis, 25 genes were found to be differentially
expressed among the three classes (Table 3). The majority of the
genes (88%) were upregulated in the benign tumours relative to
the borderline and malignant tumours, whereas only three genes
(12%) were upregulated in the malignant tumours relative to the
other tumour types. The mean expression value obtained for each
gene in the borderline class was either equal to or between that of
the benign and malignant tumour types. Comparison of the genes
upregulated in benign tumours identified by PAM with that of the
‘benign’ cluster listed in Table 2 revealed a common set of nine
genes. In addition to PAM, we used a Student’s t-test to identify
genes that were differentially expressed between benign and
malignant tumours. A set of data was extracted containing genes
that differed in mean expression by two-fold or higher between
the benign and malignant tumour types with a P-value 0.05
(Supplementary Table SI). A total of 26 genes was selected, and 15
of the 25 genes identified by PAM were contained in this list. For
each gene, the mean expression value for the LMP group was equal
to or between that of the benign and/or malignant group.
Validation by RT–PCR
From the unsupervised and supervised analyses described above,
we selected 21 genes for validation by quantitative ‘real time’ PCR
using an independent set of tumour RNA samples representing
nine benign, nine borderline and 10 malignant ovarian tumours.
The expression of these genes was measured relative to a set of
six housekeeping genes. For quantitation, a standard curve was
generated using serial dilutions of the same RNA that was used as a
reference in the microarray experiments. Of the genes that were
analysed, the mean expression value for each gene was consistent
with the trend observed in the microarray data with the mean of
the borderline tumours positioned in the middle. There was a
significant difference (Po0.05) between the means of the benign
and malignant groups for 18 of the 21 genes as determined by
ANOVA (Supplementary Table SII). The full set of RT–PCR data is
available in the Web Supplement. To demonstrate the difference
between the phenotypes visually, we applied hierarchical clustering
to the RT–PCR data (Figure 2). The resulting dendogram
consisted of two major groups: one containing the benign tumours
Table 1 Pathologic characteristics of the ovarian tumours used in this
study
Degree malignancy Subtype Number
Benign Mucinous 15
Serous 9
Clear cell 0
Endometrioid 1
Mixed/other 4
Total 29 (24%)
Borderline Mucinous 30
Serous 3
Clear cell 0
Endometrioid 1
Mixed/other 0
Total 34 (28%)
Malignant Mucinous 5
Serous 16
Clear Cell 20
Endometrioid 10
Mixed 6
Total 57 (48%)
Tumour grade Number
Well (I)
9 (17%)
Well-moderate
4 (8%)
Moderate (II)
10 (19%)
Moderate-poor
8 (15%)
Poor (III)
21 (40%)
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profile of one of the benign tumours was associated with that of the
malignant group. The borderline tumours were interspersed
among the two clusters; however, the majority (78%) was
associated with the benign tumour class.
Validation by immunohistochemistry
To validate differential expression of two candidate markers at the
protein level, we performed immunohistochemistry to detect CD24
antigen and SPARCL-1 protein in a pair of slides representing a
benign and malignant tumour (Figure 3). Weak to no signal was
detected in a slide representing benign endometrioid adenomyofi-
broma when stained with CD24 antibody, while in contrast, serous
papillary carcinoma exhibited moderate to strong CD24 staining in
the nucleus and cytoplasm. With respect to SPARCL1, strong
staining was observed in both tumour cells and stroma of the
endometrioid adenomyofibroma. Although somewhat weaker, a
similar staining pattern was observed in the malignant tumour,
with staining of both tumour and stroma.
Classification by tumour subtype and grade
Tumour subtype and grade are phenotypes designated by
microscopic analysis. Therefore, we used supervised algorithms
to determine whether molecular classifiers for these histologic
features could be extracted from the microarray data. Prediction
analysis of microarays analysis was applied to the expression data
obtained for 85 borderline and malignant tumour specimens for
which subtype information was available. The data set was split
randomly into two groups: a training set consisting of data for
63 tumour specimens (14 serous, 26 mucinous, 15 clear cell and
eight endometrioid) and a test set which contained data for 22
specimens. With respect to subtype, the relative number of
specimens in the test set was proportional to that of the training
set. Using a significance threshold of 2.1, PAM generated a set of
149 genes that distinguish the four major subtypes (Supplementary
Table SIII). This classifier correctly categorised each of the nine
mucinous tumours in the test set. However, none of the clear cell
or endometrioid tumours was correctly identified, and only 40%
(two of five) of the serous tumours were predicted correctly. A
similar approach was used to develop a classifier for histologic
Benign        56% 
Borderline   26% 
Malignant    18%
Benign          7% 
Borderline   10% 
Malignant    83%
Benign        10% 
Borderline   40% 
Malignant    50%
Group I Group II Group III
Figure 1 Unsupervised hierarchical clustering of benign, borderline and malignant human ovarian tumours. The most variable portion of the data set (147
genes) was analysed and visualised by the Cluster and TreeView programs developed by Eisen et al (1998). The relative percentage of each tumour type
within each major cluster is shown. Red, green and black pixels indicate relatively high, low and neutral expression, respectively.
Expression profiling of ovarian cancer
S Biade et al
1095
British Journal of Cancer (2006) 95(8), 1092–1100 & 2006 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sgrade. To facilitate the analysis, we combined well- and well-to-
moderately differentiated tumours with moderately differentiated
tumours to form one group (moderate group). Likewise, poor-to-
moderately differentiated tumours were combined with poorly
differentiated tumours to form a second group (poor group). The
data set was then randomly divided into a training set (38 samples)
and a test set (13 samples). Using a significance threshold of 1.7,
PAM analysis produced a set of 15 genes to serve as a classifier
(Supplementary Table SIV). Prediction analysis of the test set
revealed that only one of six moderate tumours was classified
correctly, whereas all of the seven poorly differentiated tumours
were identified correctly.
DISCUSSION
Expression profiling has proven to be a powerful tool for tumour
classification (Dubba-Subramanya et al, 2003). Following the
pioneering study of Alizadeh et al (2000), which established a
classifier for B-cell lymphomas, a number of data sets have been
generated that contain expression signatures for various biologic
and clinical tumour phenotypes. Despite these advances, however,
microarray studies are fraught with potential pitfalls that, if not
carefully considered, can lead to erroneous conclusions (Simon,
2003). These issues include experimental design, sample size, data
analysis and validation using an independent set of samples. In
the present study, we established gene expression profiles for
120 human ovarian tumours to identify determinants of tumour
subtype, grade and degree of malignancy. We employed both
unsupervised and supervised algorithms to generate a set of
candidate genes that could serve as a classifier for tumour
malignancy. As an initial step towards validating candidate genes
as tumour markers, we measured gene expression by quantitative
RT–PCR using RNA isolated from an independent set of tumour
specimens. We used this validation strategy as an alternative to
establishing a test set from the microarray data, as it represents a
more accurate method for measuring gene expression. The results
indicate that, collectively, these genes are useful markers for the
classification of ovarian tumours with respect to degree of
malignancy.
To gain insight into the putative function of some of the genes in
our classifier, we examined the literature for reports of their
involvement in neoplasia. One would predict that if a gene is lost
or down regulated in a malignant tumour, its over expression may
confer reduced proliferation, differentiation or a non-metastatic
phenotype. Conversely, genes that are up regulated in malignant
tumours may be more likely to confer a more aggressive,
metastatic phenotype. For example, we found that connective
tissue growth factor (CTGF) is highly expressed in benign tumours
relative to malignant tumours. Chang et al (2004) showed that
Table 2 Genes upregulated and associated with group I (benign cluster) and group II (Malignant cluster) as determined by hierarchical clustering
Accession no. Symbol Genes upregulated in benign tumours
AI870821 SOX10 SRY (sex determining region Y)-box 10
AA664101 ALDH1A1 Aldehyde dehydrogenase 1 family, member A1
AA477400 TPM2 Tropomyosin 2 (beta)
H99676 COL6A1 Collagen, type VI, alpha 1
R62603 COL6A3 Collagen, type VI, alpha 3
AA683077 MAPK1 Mitogen-activated protein kinase 1
H95960 SPARC Secreted protein, acidic, rich in cysteine (osteonectin)
AA490172 COL1A2 Collagen, type I, alpha 2
N62586 ERCC5 Excision repair cross-complementing rodent repair deficiency, complementation group 5
AA071473 MATN2 Matrilin 2
R61229 GATM Gycine amidinotransferase (L-arginine:glycine amidinotransferase)
AA465216 D8S2298E Reproduction 8
AA682423 MAOB Monoamine oxidase B
T68892 SFRP1 Secreted frizzled-related protein 1
T90767 CCNT1 Cyclin T1
AA490471 SPARCL1 SPARC-like 1 (mast9, hevin, SC-1)
AA778198 PBX3 Pre-B-cell leukemia transcription factor 3
N58145 LHFP Lipoma HMGIC fusion partner
W15267 LRP6 Low-density lipoprotein receptor-related protein 6
H08561 IGFBP5 Insulin-like growth factor binding protein 5
AA598794 CTGF Connective tissue growth factor
T62048 CIS Complement component 1, s
Accession no. Genes upregulated in malignant tumours
R38201 OPCML Opioid-binding protein/cell adhesion molecule-like
H97778 CDH6 Cadherin 6, type 2, K-cadherin (fetal kidney)
AI924523 NAP1 Pronapsin A
AA419229 MGC29643 Hypothetical protein MGC299643
R93509 STK4 Serine/threonine kinase 4
AA434373 ELF3 E74-like factor 3 (ets domain transcription factor, epithelial-specific)
H59916 CD24 CD24 antigen
H97778 CDH1 Cadherin 1, type 1, E-cadherin (epithelial)
AW050484 TSPAN1 Tetraspan 1
H13688 GALNT3 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 3
AA022949 GFG18 Fibroblast growth factor 18
AA405767 PAX8 Paired box gene 8
AA911661 HOXB2 Homeo box B2
AA683520 SLP1 Secretory leukocyte protease inhibitor (antileukoprotease)
AA401441 BF B-factor, properdin
W72393 RAMP3 Receptor (calcitonin) activity modifying protein 3 (RAMP3)
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disease, lymph node metastasis and shorter median survival in
lung adenocarcinoma. Furthermore, invasive and metastatic
activity was lower in tumour cells that were engineered to
overexpress CTGF. Although no specific functional data are
available, Mok et al (1994) identified DOC1 (downregulated in
ovarian cancer) using a DNA-fingerprinting approach to find
genes differentially expressed between ovarian cancer cells and
normal ovarian epithelial cells.
SPARC-like 1 (SPARCL1, MAST9, hevin, SC-1) is a member of
the SPARC family (Claeskens et al, 2001). This gene was originally
shown to be downregulated in human non-small cell lung cancer
and subsequent reports indicated that downregulation of SPARCL1
also occurs in prostate and colon carcinomas (Bendik et al, 1998;
Isler et al, 2001). This suggests that SPARCL1 inactivation is a
frequent event in tumours of epithelial origin. Consistent with
our findings in ovarian cancer, Oka et al (2001) used differential
display to show increased expression of complement component 7
(C7) in normal vs. malignant oesophageal specimens. In situ
hybridization confirmed the localisation of C7 mRNA in normal
oesophageal epithelial cells and its disappearance in tumour cells.
Two other genes that have been studied functionally with respect
to growth suppression are ephrin-B2 and cold-inducible RNA-
binding protein (Nishiyama et al, 1997; Liu et al, 2004). The latter
has been shown to be downregulated in endometrial cancer in
comparison to normal endometrium and tissue representing
endometrial hyperplasia (Hamid et al, 2003). Likewise, we found
that ephrin-B2 and CIRBP were expressed at lower levels in
malignant tumours compared to benign tumours. An effect of
cold-inducible RNA binding protein on reducing cell doubling
time was confirmed in our laboratory following transfection of the
full-length cDNA into ovarian cancer cells (data not shown).
We discovered that fewer genes were consistently upregulated
in malignant tumours relative to benign tumours. Differential
expression of these same genes has been observed by other
investigators in comparisons of normal vs malignant ovary (Welsh
et al, 2001; Adib et al, 2004). Although the experimental designs
do not enable a direct comparison with our results, we may make
inferences based on differential expression observed between
normal and malignant tumours to that of benign vs malignant
tumours. Welsh et al (2001) measured gene expression in a set of
27 serous papillary adenocarcinomas of the ovary and three
normal ovarian tissue samples. Of the 30 genes that were
considered most significantly different between the two groups,
three (CD24, PAX8, SPINT2) were among the upregulated genes
resulting from our analysis. Adib et al (2004) established
expression profiles for tissue specimens representing four normal
ovary, six primary tumour and six corresponding tumour
metastases. Consistent with our results, they observed upregula-
tion of B-factor (properdin), CD24 antigen, E-cadherin, opioid-
binding protein, preferentially expressed antigen in melanoma
(PRAME) and antileukoprotease (SLP1) in primary tumours and
metastases. Some of these genes may be specific to ovarian
tumours, whereas others may be expressed in other tumour types
relative to corresponding normal tissue. For example, CD24 is a
sialoglycoprotein that is anchored to the cell surface by a glycosyl
phosphatidylinositol (GPI) linkage and normally expressed in a
variety of haematopoietic cells. Kristiansen et al (2002, 2003, 2004)
have reported that increased CD24 expression is associated with
poor prognosis in breast, prostate, and ovarian cancer. PRAME
encodes a 509 amino-acid protein that is capable of eliciting a T-
cell response. Expression of this antigen is primarily restricted to
the testis, but has been shown to be expressed in a variety of solid
and haematologic tumours (Matsushita et al, 2003). Increased
expression of antileukoprotease (SLP1) has also been observed in a
variety of tumour types including ovarian cancer (Shigemasa et al,
2001). Devoogdt et al (2003) demonstrated that transfection of the
human SLP1 cDNA into Lewis lung carcinoma cells resulted in
increased tumourigenicity and lung-colonising potential. In
contrast, however, the protease inhibitor SPINT2 was shown to
reduce the metastatic potential of ovarian cancer cells (Suzuki
et al, 2003). This result highlights the complexity of defining the
Table 3 Identification of genes that distinguish among benign, borderline and malignant ovarian tumours by prediction analysis of microarrays
PAM Score
Accession no. Symbol Gene Benign Borderline Malignant
H08561 IGFBP5 Insulin-like growth factor binding protein 5 0.2760 0 0.0547
AA977242 CIRBP Cold-inducible RNA-binding protein 0.2298 0 0
AA459941 PEG3 Paternally expressed 3 0.2251 0 0
AA001614 INSR Insulin receptor 0.1515 0 0
AA424584 LTBP2 Latent transforming growth factor beta binding protein 2 0.1270 0 0
AA448277 FOXO1A Forkhead box O1A (rhabdomyosarcoma) 0.1233 0 0
AA481438 SERPING1 Serine (or cysteine) proteinase inhibitor, clade G (C1 inhibitor), member 1 0.1197 0 0
AA700832 RBP1 Retinol binding protein 1, cellular 0.1105 0 0
AA481026 SMARCA2 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 0.1064 0 0
AA156802 LAMB2 Laminin, beta 2 (laminin S) 0.1022 0 0
AA056232 GSTM5 Glutathione S-transferase M5 0.0977 0 0
AA679454 STAR Steroidogenic acute regulatory protein 0.0815 0 0
AA682423 MAOB Monoamine oxidase B 0.0663 0 0.0675
AA398366 SH3GL1 SH3-domain GRB2-like 1 0.0514 0 0
N78902 LEPR Leptin receptor 0.0481 0 0
AA405767 PAX8 Paired box gene 8 0 0 0.0471
AA478553 DCT Dopachrome tautomerase 0.0447 0 0
AA045735 — Transcribed sequence with moderate similarity to protein sp:P39195 0.0345 0 0
AA460833 PGCP Plasma glutamate carboxypeptidase 0.0147 0 0
AA490471 SPARCL1 SPARC-like 1 (mast9, hevin, SC-1) 0 0 0.0093
W15267 LRP6 Low density lipoprotein receptor-related protein 6 0 0 0.008
AA464856 ID4 Inhibitor of DNA binding 4, dominant negative helix-loop-helix protein 0.0036 0 0
AI934925 SLC23A1 Solute carrier family 23 (nucleobase transporters), member 1 0 0 0.0013
R38201 OPCML Opioid-binding protein/cell adhesion molecule-like 0 0 0.0012
H99676 COL6A1 Collagen, type VI, alpha 1 0.0005 0 0
The score derived from this analysis using a significance threshold of 3.1 is shown.
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and metastasis. Finally, there is evidence to suggest that E-cadherin
is associated with the malignant phenotype. In a study by
Sundfeldt et al (2001), the levels of soluble E-cadherin were
significantly higher in cystic fluid from cystadenocarcinomas and
borderline tumours compared to cystic fluid from cystadenomas.
Collectively, the association between many of the upregulated
genes that we identified and expression/function in other
published studies of tumourigenesis suggest that they may
contribute functionally to the metastatic ovarian cancer pheno-
type. Whether or not they represent useful therapeutic targets will
require further study.
Recently, Shih and Kurman (2004) proposed a model to describe
the pathogenesis of ovarian cancer based on morphologic and
molecular data. Tumours were classified into two major groups
(types I and II) with respect to potential tumourigenic pathway. In
this model, type I tumours consist of low-grade neoplasms that
undergo stepwise transformation from benign and borderline
tumours into malignant carcinomas. This group includes low
grade serous tumours in addition to tumours representing the
other major subtypes. Type II tumours consist primarily of high-
grade serous carcinomas which are inherently more aggressive and
evolve de novo from the ovarian surface epithelium or inclusion
cysts. These tumours metastasise rapidly and are associated with
a lower five-year survival in comparison to type I tumours.
Consistent with this idea, our microarray data have also defined
two major malignant tumour classes: One (Figure 1 – group II)
that contained a high percentage of high grade malignant tumours,
and the other (Figure 1 – group III) that consisted primarily of a
mixture of borderline and malignant tumours of moderate grade.
Group II contained a mixture of endometrioid and serous
tumours, whereas group III represents a mixture of tumour
subtypes. It would be of interest to determine whether these
groups arise from the type I and type II tumorigenic pathways
proposed.
A debate exists regarding which factors are of prognostic
significance in borderline ovarian cancer patients. A large retro-
spective study of 370 patients was conducted by Kaern et al (1993)
at the Norwegian Radium Hospital. Univariate analysis of this
cohort revealed several markers of prognostic significance
including FIGO stage, presence of residual tumour, surgical
procedure, tumour growth on the ovarian surface and presence
of pseudomyxoma peritonei. A more recent study by Trimble et al
(2002) found FIGO stage to be associated with survival in 2818
women with borderline ovarian tumours. Similarly, Sherman et al
(2004) reported reduced 10 year survival in distant stage vs
localised disease in a group of approximately 4500 borderline
ovarian cancer patients. To date, there have been few comprehen-
sive analyses of molecular determinants of prognosis. Our
expression profiling results indicate that as a group, borderline
tumours are heterogeneous and exhibit features of both benign
and malignant tumours. However, there were no specific markers
that distinguished borderline tumours as an independent group.
These results suggest that it may be necessary to classify borderline
tumours into two major groups: one that represents tumours with
a benign clinical phenotype (LMP benign) and one that represents
tumours that are either malignant or have a higher propensity of
becoming malignant (LMP malignant). This concept has been
supported by other studies of ovarian tumour pathology (Seidman
and Kurman, 2003). However, further analysis will need to be
carried out with a larger set of borderline tumours with recurrence
and survival data.
From our data, molecular determinants that define ovarian
tumour subtypes and grades were not as easily identified as those
that distinguish degrees of malignancy. Unsupervised clustering
did not group tumours based on subtype or grade, and we were
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STK4
PRAME
CDH1
BF
SPINT2
PAX8
SLP1
CD24
CTGF
C7
PEG3
GATM
EFNB2
CIRBP
IGFBP5
SERPING1
GSTM5
DDX24
DOC1
SPARCL1
LHFP
Figure 2 Cluster analysis of quantitative RT-PCR data obtained for 21
genes associated with the benign, borderline and malignant phenotypes.
Red, green and black pixels indicate relatively high, low and neutral
expression, respectively.
Figure 3 Validation of differentially expressed genes by immunohisto-
chemistry. (A) Representative H&E staining of a poorly differentiated
serous papillary carcinoma and a benign endometrioid adenomyofibroma.
(B) Staining of the same tumours with anti-CD24 antibody. The benign
tumour showed weak staining whereas the malignant tumour showed
moderate to strong signal. Areas of intense staining indicated by arrows.
(C) Staining of both tumours with anti-SPARCL1 antibody. The benign
endometrioid adenomyofibroma exhibited moderate to intense staining
while the serous papillary carcinoma showed moderate staining with more
prominent areas.
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supervised methods. This could be due to a variety of biological
and technical reasons. The relative magnitude of differential
expression among the genes that distinguish these phenotypes
may be relatively low. Therefore, the noise associated with the
microarray data could interfere with the identification of
such patterns. As we used RNA isolated from whole tumour
specimens, the inclusion of stromal, immunologic, and other cell
types could serve to dilute relevant gene expression signals.
The use of microdissected tissues could resolve this problem. Also,
we utilised an array containing 7000 cDNA elements. Given that
this does not fully represent the entire human transcriptome, we
may have missed relevant genes. Other groups have identified
markers that are associated with specific ovarian tumour subtypes.
For example, Schaner et al (2003), using cDNA microarray
analysis, identified a set of genes that are differentially expressed
in clear cell tumours compared to other ovarian subtypes. Of the
49 genes listed in this report, 27 of the genes were contained in our
data set; however, only one (ESR1) was significantly differentially
expressed (Po0.05) in our set of clear cell tumours. With respect
to tumour grade, we identified only one gene (GSTM2) that was
significantly different among 10 genes that were present in both
data sets. In the study by Schwartz et al (2002), a signature for
clear cell tumours was also provided. Comparison of our PAM
results with this report indicated that only nidogen 2 was shared
between the two data sets. These results underscore the importance
of validating microarray results with an independent set of
samples.
In conclusion, the results of our study demonstrate that
expression profiling is a useful method for classifying ovarian
tumour phenotypes. Although a clear expression pattern did not
emerge that could classify the individual ovarian tumours by
histologic subtype and grade, a set of genes was discovered that
could distinguish benign from malignant phenotypes. It is
important to consider that the gene expression data were collected
from whole tumour tissue rather than microdissected material. In
some instances, differential gene expression may represent
increased or decreased levels of nontumour mRNA contributed
by stromal cells in the whole tissue sample. Upon examination of a
selected set of tumours, we found that the malignant specimens
consisted of 78% tumours cells versus 45% in the benign. It is
unlikely that this difference in stromal content can account for the
relatively large differences observed in gene expression between
the benign and malignant tumours. Moreover, we were able to
demonstrate differential expression of CD24 in benign vs
malignant tumours by immunohistochemistry; however, we could
not definitively show significant differential expression of
SPARCL1, as significant positive staining was observed in stromal
cells from both the benign and malignant tumours. These findings
underscore the necessity to validate gene expression data by
immunohistochemistry or other methods in a larger set of tumour
specimens. This will be required to establish definitively the
usefulness of these determinants as diagnostic/prognostic markers
and to address sensitivity and specificity parameters of such an
assay. Overall, the incorporation of our results into those of other
investigators will be an important step in identifying a consensus
set of markers to improve both the diagnosis and management of
ovarian cancer.
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